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The prevalence of Osteoarthritis (OA) is increasing because of the progressive aging and unhealthy lifestyle. These risk factors
trigger OA by removing constraints that keep the tightly regulated low turnover of the extracellular matrix (ECM) of articular
cartilage, the correct chondrocyte phenotype, and the functionality of major homeostatic mechanisms, such as mitophagy,
that allows for the clearance of dysfunctional mitochondria, preventing increased production of reactive oxygen species,
oxidative stress, and senescence. After OA onset, the presence of ECM degradation products is perceived as a “danger”
signal by the chondrocytes and the synovial macrophages that release alarmins with autocrine/paracrine effects on the
same cells. Alarmins trigger innate immunity in the joint, with important systemic crosstalks that explain the beneficial
effects of dietary interventions and improved lifestyle. Alarmins also boost low-grade inflammation: the release of
inflammatory molecules and chemokines sustained by continuous triggering of NF-κB within an altered cellular setting
that allows its higher transcriptional activity. Chemokines exert pleiotropic functions in OA, including the recruitment of
inflammatory cells and the induction of ECM remodeling. Some chemokines have been successfully targeted to attenuate
structural damage or pain in OA animal models. This represents a promising strategy for the future management of
human OA.
1. Introduction
Osteoarthritis (OA) is the most frequent arthritic disease
with an expanding prevalence not only due to the aging
of the population in western countries and to the increas-
ing impact of some key epidemiological factors such as the
global epidemic of obesity and metabolic syndrome (and the
consequent increase of the so-called metabolic syndrome-
associated OA or metOA) but also to increased exposure to
independent risk factors that are associated to the postindus-
trial era [1].
OA heavily impacts on the expenditure of the national
health services as well as on patients’ quality of life. Cur-
rently, there are not yet true disease-modifying drugs and
in most cases the disease progresses until arthroplasty.
The bone-joint decade (2000–2010) has fostered the
research aimed at a better understanding of musculoskeletal
disorders there including OA in order to improve prevention
and treatment. Therefore, the recent years witnessed the
deepening of our knowledge of the molecular mechanisms
that are responsible for this disease. It becomes clear that
notwithstanding the initial OA triggering risk factors (aging,
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mechanical stress, genetics, and obesity), there are shared
downstream molecular modifications that affect transcrip-
tion factors and epigenetic changes, thus leading to common
dysregulation of target gene expression in joint cells and
disrupted cellular functions [2]. Moreover, it is now a matter
of fact that OA represents a disease of the whole joint organ,
with important crosstalks between various tissues. There is
also an increasing awareness of the “systemic” dimension of
OA, which is supported by the evidence of crosstalks between
“local” joint tissue inflammation and “systemic” inflamma-
tion. This is in the frame of a generalized failure of postmito-
tic tissues supported by shared mechanisms, such as the
impairment of major homeostatic cell responses [3, 4] that
lead to accumulation of oxidative stress, cell dysfunction,
and senescence. These stress signals are perceived as
“danger-associated molecular pattern” and thus are able to
trigger macrophage activation and innate immunity. Nota-
bly, a recent proteomic study performed in the sera of OA
patients pointed at a cluster of three proteins as highly indic-
ative of radiographic OA and therefore useful as convenient
biomarkers for screening and early diagnosis. This cluster
contains an alarmin (S100A6) and a complement protein
(C3), two proteins able to trigger innate immunity, besides
inter-alpha-trypsin inhibitor heavy chain 1 (ITH1) that acts
as a protease inhibitor [5].
A putative successful therapeutic strategy should there-
fore combine several lines of actions targeted at multiple
levels with the aim of restoring “joint” homeostasis in
the context of a “systemic” homeostasis. This implies dra-
matic changes in lifestyle (diet, exercise, healthy microbi-
ota, and weight loss) that ultimately have the potential of
reducing the activation of the innate immunity in joint
and nonjoint tissues.
Basic research deepened our understanding of OA
pathogenesis, and major achievements in defining critical
targets have been obtained in matching findings derived
from human tissues with those derived from several differ-
ent animal models. A wide array of OA animal models
either surgical or chemical have been developed, but the
destabilization of medial meniscus (DMM) carried out in
mice at the time of skeletal maturity is recognized as the
method of choice for mimicking human pathology and
its progression from mild-to-moderate OA (4 weeks) to
moderate-to-severe OA (8 weeks) [6]. DMM should be a first
choice to challenge mice with gene deletions of potential
targets in OA [7].
Many review papers have reported an updated under-
standing of the role of signaling pathways [8] or cytokines
[9] in OA pathogenesis, but a cumulative picture of cellular
and molecular mechanisms of oxidative stress in articular
cartilage in relation to aging, activation of innate immunity,
metabolism, and cellular survival/longevity was lacking. In
this review, we summarized recent information linking
aging, metabolic deregulation, oxidative stress, and inflam-
mation, with particular focus on selected chemokines, which
have a role in pain. As long as OA can be considered as
resulting from loss of tissue homeostasis, the above-
mentioned pathogenetic mechanisms all result in an
accelerated cartilage aging.
2. OA in the Context of Aging and
Metabolic Deregulation
2.1. OA and Loss of Maturational Arrest. OA is the joint
disease most closely correlated with aging. The status of
healthy articular cartilage is actively kept in virtue of molec-
ular constraints that prevent the progression of chondrocytes
into their default route to hypertrophy and terminal differen-
tiation prior to endochondral ossification [10]. Indeed, along
OA initiation and progression, chondrocytes undergo a
switch in gene expression from an “anabolic” to a “catabolic”
pattern [10], recapitulating what occurs in growth plate cal-
cification, the latter being considered as a “developmental
model” for OA pathogenesis [11]. Chondrocyte progres-
sion from a “resting” to an “activated” state in either
growth plate calcification or OA cartilage degeneration is
indeed accompanied by the same shared signature of
marker genes (extracellular matrix (ECM) proteins or
transcription factors) and related phenotypic changes and
cell reaction patterns such as cell proliferation or apoptotic
cell death [12]. The loss of this “maturational arrest” of
articular cartilage in all the species is somehow pro-
grammed to occur at a given age that follows the decline
of the reproductive age and depends on the life expectancy
of the species. On a general basis, life expectancy and lon-
gevity of a species have been connected to the differential
capacity of its cells to handle oxidative damage to the
DNA [13–16] in the form of double-strand breaks.
2.2. Oxidative Stress, NF-κB Activation in OA, and
Differential IKK Role. The role played by oxidative damage
is central in OA and in the other age-related diseases. Indeed,
at the cell level, oxidative damage of genomic and mitochon-
drial DNA (mtDNA) triggers a DNA damage response
and activation of the nuclear factor-κB (NF-κB) pathway
[3, 17], the master regulator of inflammation. NF-κB is a
family of transcription factors that have a central role not
only in the proinflammatory stress-related responses of
chondrocytes to extra- and intracellular insults but also in
the control of their differentiation program [17, 18]. The acti-
vation of NF-κB is triggered by the signalosome complex, a
molecular switch controlled by two main serine threonine
kinases able to remove NF-κB inhibitors that block NF-κB
transcriptional activities: IKKβ and IKKα. These kinases
present peculiar functional features, with regard to the type
of upstream activating stimuli, signaling intermediates, and
downstream NF-κB activated heterodimers. IKKβ is the
kinase that triggers the “canonical pathway” of NF-κB activa-
tion that controls most of the immediate inflammatory,
stress-like responses in vivo and in vitro. IKKα is required
for the noncanonical or alternative pathway, which is delayed
and requires proteolytic processing. In some cellular settings,
IKKα may also intervene in the canonical inflammatory
pathway [19]. Moreover, as reviewed in [17, 20], IKKα has
other functions that boost NF-κB transcriptional activities,
including the inhibition of histone deacetylases and the phos-
phorylation of serine 10 on histone H3, thereby promoting a
transcriptionally permissive conformation of the chromatin.
H3 phosphorylation is required to activate promoters of
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some inflammatory genes, there including IL-6, IL-8, and
MCP-1 [21]. These activities are played by IKKα in the
nucleus, and indeed, quoting from http://proteinatlas.org,
IKKα “is mainly localized to the nucleoplasm and in addi-
tion localized to the cytosol and vesicles” (https://www.
proteinatlas.org/ENSG00000213341-CHUK/cell), while
IKKβ is only detected in the cytosol (https://www.
proteinatlas.org/ENSG00000104365-IKBKB/cell) in keep-
ing with its activity almost only implicated in the frame-
work of NF-κB activation. The pleiotropic activities of
IKKα are presented in http://reactome.org and span far
beyond signal transduction, differently from IKKβ.
Our work has also recently highlighted other IKKα activ-
ities relevant for OA that are kinase and NF-κB independent
and that control ECM remodeling [22, 23] via collagenase
activation. Therefore, IKKα targeting could be effective in
reducing OA progression, yet sparing the prosurvival and
antiapoptotic activities that are instead uniquely controlled
by IKKβ [20]. Indeed, pharmacological IKKα inhibition
attenuated OA progression in the DMM model, where OA
progression itself is accompanied with increased expression
of IKKα [24].
IKKα is therefore a candidate drug target for human
OA. IKKα could be locally targeted to obtain at the same
time reduction of p53 [25] and NF-κB activity [17, 20],
together with the inhibition of its ECM remodeling pro-
moting effects [23].
2.3. The IKKα/p53 Connection, Oxidative DNA Damage,
Obesity, and Cell Senescence. The connection linking oxida-
tive stress and inflammation has been reviewed in [26]. This
results in cell dysfunction at multiple levels [3]. The DNA
damage response activates and stabilizes p53 through post-
translational modifications and prevents its degradation by
proteasome. An intriguing crosstalk has been described
between IKKα and p53: under exposure to oxidative stress,
the redox-sensitive PKCδ activates IKKα and induces its
translocation to the nucleus, where it phosphorylates and
activates p53 [25]. As a function of the DNA damage
magnitude, p53 may orchestrate homeostatic activities or
dysfunctional responses, such as irreversible cell cycle arrest,
senescence, or apoptosis [27] (Figure 1). A recent report
explored the correlation of gene and protein expression of
cyclin D1, cyclin-dependent kinase 4, and p53 in cartilage
derived from a large cohort of patients and healthy controls
and showed that cyclin D1 and cyclin-dependent kinase 4
are negatively correlated with the disease grade in knee OA,
in agreement with increased p53 [28].
Oxidative damage of genomic DNA and of mtDNA
has been found in OA cartilage [29, 30]. Noteworthy, the
level of oxidative damage to mtDNA has been found cor-
related with BMI of the patients and associated to markers
of DNA damage response, hypertrophy, and senescence
[29]. This discloses a molecular pathogenesis peculiar for
the so-called metOA whose development is indeed antici-
pated compared to posttraumatic, aging, genetic, or crystal
OA phenotypes [31]. Metabolic syndrome (MetS) is a
global epidemic (23% of the general population). White
adipose tissue (WAT) plays an endocrine role in MetS:
increased M1 macrophages and adipose-derived stem cells
(ASC) release inflammatory cytokines, chemokines, and adi-
pokines. Adipocytes and possibly other WAT cells [32]
release circulating microRNAs (miR). Circulating (blood or
exosomal) miR dysregulation in MetS has been already
reported [33]. Among their putative targets, there are pro-
teins which may afford protection in conditions of metabolic
or oxidative stress, such as AMP-activated protein kinase
(AMPK), PPARγ, and PKCε [33]. Their dysfunction might
result in increased DNA damage and senescence in ASC,
conditioning their stemness and their trophic activity while
dysfunction of these proteins in postmitotic tissues such as
cartilage disrupts the existing cellular homeostasis [34, 35].
Reduced AMPKα1 [36] and PPARγ1 [37] expression in
chondrocytes as a function of OA severity has been
already reported. Moreover, adipose tissue has a role in
OA development, acting as an endocrine organ and pro-
ducing adipokines and inflammatory mediators. Leptin
activates the JAK/STAT pathway and proinflammatory
response and chondrocytes express functional leptin recep-
tors [38]. Many studies evidenced a role for leptin in alter-
ing chondrocyte function, via increased expression of ECM
degradative enzymes, namely, matrix metalloproteinases
and enzymes of the “a disintegrin and metalloproteinase
with thrombospondin motifs (ADAMTS)” family. Leptin
has been pointed out as a necessary factor for OA devel-
opment in in vivo animal models of obesity, while studies
on patients support its role in human OA, with a direct
correlation between serum leptin levels and diminished
cartilage thickness [39, 40].
2.4. Metabolic Deregulation in OA Pathogenesis and the
Nutraceutical Approach to OA Management. Obesity is asso-
ciated with a status of systemic inflammation affecting the
function of many postmitotic tissues, there including the
cardiovascular system. Indeed, the incidence of OA is dou-
bled in people with cardiometabolic clustering (higher or
equal to 2 of the following: low levels of high-density lipo-
protein cholesterol; elevated levels of low-density lipoprotein
cholesterol, triglycerides, blood pressure, C-reactive protein,
waist-to-hip ratio, or glucose; or diabetes mellitus) [41]. This
opens new perspectives in the treatment of these diseases
that share similar mechanisms leading to target tissue cell
dysfunction and boosts the relevance of developing thera-
peutic approaches in the perspective of a precision medicine.
On a general basis, the use of mere antioxidant supplements
in clinical trials has led to weak and inconsistent results [42],
while an integrated lifestyle approach including dietary
intervention with nutraceutical implementation, physical
exercise, and caloric restriction may increase cell homeo-
static activities [43].
The ability of some nutraceuticals (in particular polyphe-
nols) to affect chondrocyte homeostatic activities includes
functional effects at multiple levels in the cells, interfering
with major inflammatory signaling pathways [44] and exert-
ing a nutrigenomic/epigenetic control [45]. Recent evidence
has shown the ability of hydroxytyrosol to influence the epi-
genetic regulation of small noncoding RNAs, thus rescuing
homeostatic activities in chondrocytes [46, 47].
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Many deranged metabolic factors such as an hyperlip-
idemic environment, high levels of cholesterol and glu-
cose, and oxidized low-density lipoproteins may directly
impact on chondrocyte health and contribute to OA
pathogenesis [48].
High dietary intake of total fat and saturated fatty acid
(SFA) has been recently put in correlation with progression
of knee OA [49]. The same study also reported that dietary
intervention with higher intake of monounsaturated fatty
acid (MUFA) or polyunsaturated fatty acid (PUFA) or higher
PUFA/SFA ratio was associated with reduced OA progres-
sion and joint space narrowing. Another critical factor is rep-
resented by the plasma ω6 :ω3 ratio that positively correlates
with pain and inflammation [50]. In obesity-associated OA,
adipose tissue functions as an endocrine organ and contrib-
utes to low-grade inflammation, also enhanced by a M2 to
M1 switch of resident macrophages. Importantly, ω6 or ω3
PUFA entering the same metabolic route in adipocytes yields
proinflammatory or anti-inflammatory mediators, respec-
tively [51], with relevant systemic consequences and differen-
tial impacts on joint tissues. The mechanisms underlying
these effects on OA patients have been explored in vitro
and in vivo in animal models.
The dose-dependent increased release of reactive oxygen
and nitrogen species (ROS and RNS) and inflammatory cyto-
kines by chondrocytes exposed to mixtures of free fatty acids
(FFA) including palmitate has been recently shown in vitro
[52] and OA development in rats fed with high-SFA diet
Nutraceuticals or dietary restriction
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Figure 1: Failure of major homeostatic mechanisms contributes to OA pathogenesis. Failure of major homeostatic mechanisms (proteostasis
and DNA damage repair networks and mitochondrial respiratory metabolism) in articular chondrocytes is caused by aging or conditions that
accelerate tissue aging, such as the obesity-associated systemic low-grade inflammation and/or dietary factors (dyslipidemia and/or
hyperglycemia) that impact on mitochondrial function. (a) Homeostasis is tightly controlled by balance between the insulin/IGF_mTOR
signaling and SIRT1. In conditions of homeostasis normal mitochondrial function, biogenesis and autophagy (mitophagy) guarantee that
the level of ROS is kept to the minimum required for intracellular signaling. Both genomic and mtDNA are preserved from oxidative
damage. Proteostasis is guaranteed by the correct functioning of the unfolded protein response and clearance via autophagy or the
ubiquitin-proteasome system. (b) Deranged metabolic factors together with aging contribute to mitochondrial dysfunction, accumulation
of ROS and RNS that increase the level of protein misfolding and aggregation, and impact on the integrity of both mitochondrial and
genomic DNA. Accumulation of DNA damage cannot be efficiently corrected because mitochondrial dysfunction leads to failure of the
energy supply required by the DNA damage response. Persistent DNA damage is responsible for chronic NF-κB activation, and
inflammation, leading to the “metabolic syndrome.” A positive feedback loop between metabolic syndrome and inflammation is even
worsened by excessive ROS and RNS produced by the dysfunctional mitochondria. Persistent DNA damage is also responsible for p53
activation, with functional consequences for the cells that include cell cycle arrest, senescence, or apoptosis according to an increasing degree.
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Figure 2: (a) Sources of ROS in the chondrocyte. The major sources of ROS are the mitochondria, during the OXPHOS. In addition, ROS can
be generated at the level of the endoplasmic reticulum (ER), in condition of ER stress. An additional source is represented by the peroxisome,
during the β-oxidation of long chain-fatty acids (LCFA), particularly under conditions of excess LCFA load. Various enzymes, with different
cell location may also generate ROS. (b) Production of ROS and RNS involved in OA pathogenesis, and major detoxifying enzymes. The first
generated ROS is the superoxide (O2
−) that is either rapidly transformed into hydrogen peroxide (H2O2) by the enzymes of the superoxide
dismutase (SOD) family or can act as a precursor for peroxynitrite (ONOO−) formation when joined to nitric oxide (NO), produced by
the enzymes of the nitric oxide synthase (NOS) family. Because of unpaired electrons, free radicals are very reactive and can damage cell
components. In chondrocytes, iron Fe2+ and H2O2 release hydroxyl radicals (OH
−) that react with unsaturated fatty acids of membrane
lipids, thus forming lipid radicals (RO•, ROO•). ROS are neutralized by scavenging systems, namely, SOD, catalase, glutathione
peroxidase, glutathione reductase, and reduced glutathione.
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has been reported in vivo [53] (see Figure 2). Palmitate has
also proapoptotic and proinflammatory activities [54] that
are reduced after inhibition of Toll-like receptor (TLR) 4.
Recent evidence has also indicated that high choles-
terol levels impact on mitochondrial health, thus leading
to increased ROS production and an anabolic-to-catabolic
switch. This condition is amenable for treatment with
mitochondria-targeted antioxidants [55]. Moreover, a higher
expression of miR33a and its host gene SREBP2 in OA
compared to normal cartilage has been reported, together
with information of the contribution of this axis to OA
pathogenesis [56, 57].
The hyperglucidic-mediated dysregulation of chondro-
cytes has also been recently connected to derangement of
the Nrf-2/HO-1 axis, a fundamental pathway in antioxidant
protection [58]. Moreover, sustained hyperglycemia leads to
increased level of glucose derivatives (advanced glycation
end-products (AGEs), sorbitol, and diacylglycerol (DAG))
able to promote the activation of several pathways triggering
inflammatory processes as reviewed in [59].
High levels of fatty acids or glucose may also worsen their
damaging activity by additional mechanisms, there including
a depressive activity of key metabolic stress regulators. In adi-
pose tissue, AMPK is rescued by ω3 PUFA [51]. High levels
of glucose may contribute to an altered metabolism in OA
chondrocytes favoring glycolysis and depressing oxidative
phosphorylation. This leads to impaired mitochondrial
metabolism and drives to mitochondrial damage, associated
to decreased levels of AMPK, SIRT-1, and PGC-1α, the mas-
ter regulator of mitochondrial biogenesis [60] (Figure 1).
PPARγ is also reduced by high levels of glucose in chondro-
cytes [61].
2.5. Proteostasis and Metabolic Stress Management. Aging is
also characterized by a collapse in proteostasis, intended as
“protein homeostasis,” a tight regulation of protein fate from
biogenesis to degradation. Proteostasis is guaranteed by the
correct functioning of the unfolded protein response
(UPR), autophagy, the ubiquitin-proteasome system, and
the lyosomes. Alteration in these pathways is a source of
stress for proteins, endoplasmic reticulum (ER), and mito-
chondria (Figure 1). Proteostasis impairment is involved in
OA pathophysiology [62], since it leads to increased oxida-
tion of proteins and alteration of homeostatic pathways.
Chaperone and cochaperone proteins intervene in main-
taining the “proteostatic network,” altered in aging and dis-
ease. Several stressors are able to trigger the heat shock
response pathway (HSR) [63]. Its activation implicates chro-
matin remodeling to promote the transcription of heat shock
proteins (HSPs), thus increasing stress resistance. HSPs are a
family of highly conserved proteins, classified according to
their molecular weight (HSP100, HSP90, HSP70, HSP60,
HSP40, and small HSPs). They orchestrate proteome mainte-
nance not only in de novo folding and protein trafficking but
also in protein degradation and in preserving autophagic
machinery components [64]. Failure of the proteostasis net-
work is a programmed event that occurs in both develop-
ment and in aging [65]. Indeed, altered chaperone
expression has been observed in aged animal models and in
senescent human cells [63]. A significant decrease in HSP70
expression has been reported in senescent cells derived from
degenerated human intervertebral disc annulus [66].
AMPK and SIRT1 are the main bioenergy sensors that
not only react to changes in energy balance but also in
inflammatory processes and cell stress. SIRT1 is reduced by
aging, and this impacts on proteostasis via reduction of the
activity of the heat shock factor 1 (HSF1) and of the FOXO
pathway [67]. Impairment of AMPK activity in cartilage pro-
motes ECM degradation. AMPK has been found reduced in
human OA as a consequence of low-grade inflammation
[36]. AMPK is also affected by age and age-related accumula-
tion of DNA breaks. The latter indeed induce DNA PK
phosphorylation of HSP90α that is then able to exert an
AMPK-inhibiting activity [68].
Specific increase and activation of HSP factors like
HSP70 and HSF1 have been observed in synovial tissues of
rheumatoid arthritis but not in OA [69]. However, in a rat
OA model, increased expression of HSP70 as induced by
the proteasome inhibitor MG132 reveals a local protective
effect on matrix degradation and apoptosis [70]. This is in
keeping with evidence pointing at a chondroprotective role
of the chaperone protein HSP70 against biomechanically
induced OA in rats [71]. The protective activity of HSP60 is
instead acted through the reduction of SOX9 ubiquitination
[72]). TRAP1, a chaperone protein of the HSP90 family with
antioxidant and antiapoptotic activities and specifically
expressed in mitochondria, was found upregulated in human
OA chondrocytes [73]. On the other hand two proteomic
studies of another group have instead identified two small
HSPs that are reduced in OA chondrocytes to an extent that
is associated with the severity of the disease. αB-cristallin-
reduced expression impacts on ECM homeostasis [74], while
the small chaperone HSP27 is involved in chondrocyte
response to IL-1β [75].
SIRT1 expression is reduced in both human OA cartilage
and in knee cartilage of both OA mouse model and aged
mice, thus strongly suggesting SIRT1 involvement in OA
development. Indeed, Sirt1 knockout mice developed accel-
erated OA progression both in cartilage-specific or whole
organism genetic models [76–78]. Recently, a wide study on
human OA cartilage has negatively correlated SIRT1 expres-
sion with disease severity [79]. Together with the pivotal role
in maintenance of mitochondrial homeostasis [80], SIRT1 is
involved in activating HSF1 transcription and proteostasis,
particularly preventing ER stress. In OA, articular chondro-
cyte UPR defective activity enhances ER stress thus leading
to misfolding of ECM proteins [62].
3. OA and Oxidative Stress and Senescence
3.1. Sources of ROS and Major ROS Scavenging Systems in the
Cell. A recent definition of oxidative stress is “an imbalance
between oxidants and antioxidants in favour of the oxidants,
leading to disruption of redox signaling and control and/or
molecular damage” [81] and is strongly associated with aging
and age-related diseases, including OA [42].
ROS production occurs mainly in mitochondria through
the mitochondrial respiratory chain and the oxidative
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phosphorylation (OXPHOS), but ROS can also be generated
by NADPH oxidase, xanthine oxidase, and other sources
(Figure 2(a)). It has been shown that the expression of some
of these prooxidant enzymes increases in synovial membrane
of OA patients [82]. The NADPH oxidase family comprises
different members with peculiar cell localization, ROS prod-
ucts, and regulation. Among others, a function of the
NADPH enzymes is to act as key modulators of signal trans-
duction pathways. One emerging activity is the reversible
posttranslational oxidative modification of several proteins
such as via sulphonylation of conserved cysteine residues.
This however may shift into a pathological role after exces-
sive activation under chronic stress. Indeed, NADPH oxidase
4 (Nox4) has been recognized as contributing to OA patho-
genesis, since its overexpression leads to increased ROS and
matrix metalloproteinases (MMPs) [83] and has been pro-
posed as a therapeutic target in OA.
The first generated ROS is the superoxide (O2
−)
(Figure 2(b)) that is either rapidly transformed into hydrogen
peroxide (H2O2) by the enzymes of the superoxide dismutase
(SOD) family [84] or acts as a precursor for peroxynitrite for-
mation (ONOO−) when joined to nitric oxide (NO), pro-
duced by the enzymes of the nitric oxide synthase (NOS)
family [85].
The main cartilage damaging ROS detected in chon-
drocytes are hydrogen peroxide and peroxynitrite [86,
87]. Because of unpaired electrons, free radicals are very
reactive and can damage cell components. In chondro-
cytes, Fe2+ and H2O2 release hydroxyl radicals (OH
•) that
react with unsaturated fatty acids of membrane lipids, thus
forming lipid radicals (RO•, ROO•). ROS are neutralized
by scavenging systems, namely, SOD, catalase, glutathione
peroxidase, glutathione reductase, and reduced glutathione
(Figure 2(b)). Several studies carried out in human OA
cartilage and experimental animal models reported a limited
antioxidant capacity of SOD, catalase, and the glutathione
systems [88, 89]. Therefore, oxidative stress leads to mem-
brane and nucleic acid damage and, also, breakdown of
extracellular components, including proteoglycans and col-
lagens. In addition, oxidative stress further sustains an
anabolic-to-catabolic switch, with downregulation of gly-
cosaminoglycan and collagen synthesis and upregulation
of MMP and aggrecanase release. The final outcome is
cartilage derangement and destruction. The evidence of
mitochondrial dysregulation is supported by a characteristic
mitochondrial protein profile in proteomic analysis of
human OA samples. This confirms that redox imbalance is
a key factor in OA pathogenesis, as evidenced by a reduction
in SOD2 (the mitochondrial SOD) expression in superficial
cartilage area [73].
3.2. Oxidative Damage to Genomic and Mitochondrial DNA
and Cell Senescence. The increased ROS burden of aged cells
[90] may be responsible for oxidative damage of both geno-
mic and mtDNA. However, it is recognized that mtDNA
damage is more extensive and persists longer than nuclear
DNA damage in human cells [91, 92]. The key role of oxi-
dative damage to mtDNA in OA is supported by the evi-
dence of differential disease susceptibility of different
mtDNA haplogroups [93, 94]. In addition, mitochondrial
biogenesis is impaired in OA [95]. Therefore, chronic oxi-
dative stress maintains a positive feedback loop with mito-
chondrial dysfunction, increased ROS, and persistent
mtDNA damage, recognized to be a hallmark of chronic
degenerative diseases. This emphasizes the critical role of
autophagy of dysfunctional mitochondria (mitophagy) in
the rescue of chondrocyte homeostasis. The mtDNA dam-
age is in turn responsible for the senescence of OA chon-
drocytes, a condition of proliferative arrest not due to
telomere shortening after a limited number of division
(intrinsic senescence) but rather to an accumulation of
DNA damage (extrinsic senescence) following exposure to
stress-inducing factors.
Occurrence of in vivo telomere shortening in OA
chondrocytes has been reported by some investigators
[96]. Indeed, since the ends of chromosomes are particularly
sensitive to oxidative stress, this can result in telomere
shortening similar to that seen with replicative senescence
[97, 98]. Recently, rather than to mature chondrocytes,
critical susceptibility to telomere attrition and senescence
has been attributed to a pool of progenitor cells whose
magnitude increases along disease progression [99]. Telo-
mere attrition in OA chondrocytes has been questioned by
other studies that instead found that increased oxidative or
genotoxic stress leads to “stochastic” genomic DNA damage
in the OA compared to normal chondrocytes, responsible
for heterogeneity of gene expression in chondrocytes with
no evidence of critical telomere shortening [30].
The effects of oxidative stress have been evaluated in vitro
by other studies. Susceptibility to the oxidative stimuli
depends on culture conditions. A fundamental issue to keep
in mind is that chondrocytes change their differentiation
status in vitro; therefore, to obtain reliable information, it
is important to grow them in culture conditions that allow
to keep/recover a proper phenotype, that is, at high density or
in 3-D [100]. It is interesting to underline that chondrocytes
are inherently quite resistant to oxidative stimuli (e.g., H2O2)
that induce apoptosis in a dose- and time-dependent manner
[101]. To obtain significantly increased chondrocyte apopto-
sis at high density, as much as 500 μMH2O2 must be kept for
24 hours [101], or in any case, a consistent time windowmust
be allowed to observe the effect.
Telomere attrition in vitro has also been evaluated: chon-
drocytes cultured within their native ECM were exposed to a
long-lasting oxidative stimulus. Then, the cells were recov-
ered from the tissue by means of enzymatic digestion, and
H2O2-induced telomere attrition was assessed [102] together
with the protective effect of ascorbate delivery.
Senescent OA chondrocytes express the senescence-
associate secretory phenotype (SASP) [103] that features an
overproduction of inflammatory cytokines, matrix degrading
enzymes, and ROS and is sustained by the upregulation of the
inflammatory pathways that participate in the “aging stress
response” [3]. Therefore, senescent chondrocytes are able
to affect the surrounding microenvironment, determine a
senescent status of cartilage precursor cells, and even trigger
OA when transplanted in healthy joints [104]. This suggests
that targeting senescent cells could be an attractive
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therapeutic strategy in OA. Indeed, a recent report ele-
gantly demonstrated that in a model of surgically induced
OA, a significant number of senescent cells accumulate in
cartilage and synovium, and selective targeting of these cells
with the newly described senolytic drugs reduces progres-
sion, pain, and inflammatory/degradative activities, while
promoting a regenerative environment [105].
Furthermore, along with differentiation progression
and under the effects of inflammatory stimuli, human articu-
lar cartilage shows increased expression of senescence
markers [106] that correlates with disease severity [107]. In
keeping with this information, epigenetic (miR-mediated)
mechanisms link senescence and chondrocyte terminal
differentiation-associated matrix remodelling in OA [108].
Noteworthy, a healthier phenotype may be rescued through
p16INK4a-specific siRNA in vitro [106].
An increase of oxidative activity of the mitochondria is
also sustained by inflammatory stimuli that lead to glycogen
synthase kinase 3 (GSK3) inhibition [109]. Indeed, inactiva-
tion of GSK3 is responsible for mitochondrial activation, per-
sistent production of mitochondrial ROS through decreased
complex IV activity, and cell senescence [29, 110]. Inflamma-
tion and oxidative stress are interdependent and boost each
other, sustained by ROS production and antioxidant deple-
tion [26]. In line with this concept, expression of the NALP3
inflammasome has been found strictly correlated with that of
prooxidant enzymes in the synovium of knee OA [82], thus
further confirming that oxidative stress sustains inflamma-
tion and degradation of the articular cartilage.
4. Low-Grade Inflammation in OA
4.1. The Role of Innate Immunity and of the Macrophages
in OA. Only a few decades ago, the disease that repre-
sents the leading cause of chronic disability of the elderly
was called “osteoarthrosis,” to indicate the prevalence of
degenerative over inflammatory processes in its pathogen-
esis, at least with regard to lack of the classical signs
rubor et tumor cum calor et dolor that are instead evident
in the so-called inflammatory arthritides. However, an
expanding body of findings collected in recent years points
at the molecular evidence of inflammation in OA chon-
drocytes. These cells have been resembled to activated
macrophages because of the shared inflammatory media-
tors that are able to release, and also other functional
properties [111].
In recent years, increasing evidence of the pivotal role of
NF-κB [17, 22] in OA pathogenesis has shed light on several
molecular mechanisms responsible for cartilage derange-
ment. Interestingly, enhanced and coordinated in vivo
expression of the NF-κB target gene inducible nitric oxide
synthase (iNOS) and the prototypical inflammatory cyto-
kines (IL-1β and TNFα) in OA chondrocytes or in AR syno-
viocytes indicated that the major focus of OA inflammation
was the cartilage, as opposed to the synovium in inflamma-
tory arthritides [112]. However, to date, OA is considered
as a whole organ disease of the joint, with important cross-
talks from the synovium and the subchondral bone [113].
Occurrence of synovitis with mononuclear cell infiltration
always precedes the development of radiological changes in
human OA while in animal models of surgically induced
OA, ablation of factors critical for macrophage recruitment
ameliorates OA progression [114], thus hinting at a role for
“innate” immunity in OA pathogenesis. Indeed, in both
human (patients with meniscal tears, a condition that may
precede OA development) and animal DMM [6] models of
OA initiation, the extent of synovitis is correlated with pain
and dysfunction and its molecular characterization reveals a
unique chemokine signature [115, 116]. The chronic and
low-grade inflammation present in OA synovium is pri-
marily innate and secondarily adaptive. Despite the extent
of the infiltrate being lower in OA compared to RA, some
features are characteristic of OA synovium: the number of
mast cells is higher [117]. Alteration of both conventional
and nonconventional Th subsets suggests a role of T cells
in OA onset and progression [118]. A recent paper indicated
that in infrapatellar fat pad there is an increase of infiltrating
CD8+ T cells that correlates with the radiological score
[119]. B cells, plasma cells, natural killer cells, dendritic cells,
and granulocytes are also occasionally present. Innate immu-
nity is the first line of defense in the body that intervenes
when physical and chemical barriers fail. Innate immunity
is mostly driven by the recruitment and activation of mac-
rophages that trigger inflammation with the aim to get rid
of the noxae. However, a targeted macrophage depletion
strategy proved to be unsuccessful and even worsened
the inflammation status suggesting that macrophages also
exert homeostatic activities [120].
4.2. Alarmins and Chemokines. Macrophages detect con-
served pathogen motifs (PAMPs or pathogen-associated
molecular patterns) via invariable pattern recognition recep-
tors (PRRs). The best known class of PRRs corresponds to
special receptors known as Toll-like receptors (TLRs), able
to recognize bacterial or viral components such as lipopoly-
saccharide (LPS) or double-stranded RNA (dsRNA). TLR
activation then induces macrophages to secrete cytokines
(small molecules involved in cell signaling and attraction),
as well as to phagocytose the infected cells. The innate
immune system is also required to activate the “adaptive”
immune system. TLR activation involvement in both synovi-
tis activation and OA development has been extensively
reviewed in [121, 122] and connected to ECM degradation
products such as hyaluronan and fibronectin.
PRRs are also able to recognize damage-associated
molecular patterns (DAMPs or alarmins), molecules that
are produced and released during tissue damage with the
aim of orchestrating tissue repair. DAMPs include the high-
mobility group box 1 (HMGB1) and the S100 family pro-
teins. Their pivotal role in disease development has been
recently elucidated [123].
Alarmins are able to trigger both synovial macrophages
(via TLR2 and TLR4) and chondrocytes (via TLR2, TLR4,
and RAGE), thus sustaining both cartilage degradation and
synovial inflammation. The crucial role of alarmins is sup-
ported by the evidence that the development of collagenase-
induced OA has been blocked by the delivery of an inhibitor
of S100A9 [124].
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Among alarmins, HMGB1 has been shown to increase
chemokine production by chondrocytes [125]. Moreover,
HMGB1 has the ability to form complexes with either IL-1
or LPS, thus enhancing their inflammatory effects on syno-
vial fibroblasts [126]. HMGB1 is a highly conserved nonhis-
tonic nuclear protein that primarily acts as a chromatin
binding factor to promote protein assembly at specific
DNA targets. HMGB1 has important intracellular and extra-
cellular functions. HMGB1 is passively released from
necrotic cells and actively secreted by activated macrophages.
In cartilage, stage-specific HMGB1 expression and release
regulate endochondral ossification [127]. At the extracellular
level, HMGB1 may serve as an inflammation promoting
cytokine but also as a danger signal, and its potential as a
therapeutic target in rheumatic diseases has already been
reported [128–130]. In comparative studies of mRNA
expression of normal versus OA cartilage, an inverse trend
was found between the procatabolic HMGB1 and the proa-
nabolic HMGB2. Besides cartilage, HMGB1 is expressed also
by synovial cells, and its concentration in the synovial fluid
has been related to OA severity [131].
Addition of HMGB1 to cultures of human chondrocytes
dramatically increased the expression of certain known NF-
κB targets, including iNOS and the chemokines that are
selectively increased in OA chondrocytes, that is, IL-8,
MCP-1, MCP-2, MIP-3α, MIP-1α, RANTES, and GROα
[125]. Interestingly, most of these chemokines belongs to
the SASP, namely, the subset of molecules that show high
increase (more than 4-fold) [103] (Figure 3). The expression
of most of these molecules appears increased in OA com-
pared to normal chondrocytes [132] or under the effect of
chondrocyte activation with inflammatory stimuli [133,
134]. Since hypertrophy plays a pivotal role in OA pathogen-
esis and hypertrophic chondrocytes release large amounts of
HMGB1 [127], it is conceivable that this mechanism greatly
contributes to maintain the deranged OA chondrocyte
transcriptisome [135].
The expression of chemokine receptors on chondrocytes
has been reported several years ago together with the first
findings of an increased expression in OA compared to
healthy cartilage of some of these receptors [136] and their
contribution to OA pathophysiology [137–139].
Chemokines represent a large molecule family of
increasing size and complexity [140] that have been firstly
described as having a role in leukocyte traffic but now rec-
ognized as able to affect many functions in a variety of tis-
sues, including joint tissues. Most of these molecules share
some basic features: the small size, the ability to bind to
seven transmembrane G-protein coupled receptors to acti-
vate intracellular responses and to exploit binding to sul-
fated glycosaminoglycans (abundant in cartilage ECM)
that act as coreceptors and determine haptotactic gradients
around the chondrocytes.
In healthy cartilage where ECM is intact and highly orga-
nized, chemokines (7–9 kDa) have a higher access to the
embedded chondrocytes compared to larger size cytokines,
such as IL-1β (17 kDa).
The role of chemokines in OA has been recently
reviewed and disclosed on the basis of cumulative evidence
derived from both findings obtained in patients and evi-
dence obtained in animal models of OA [141]. The sever-
ity of human OA as assessed by mean of the radiological
score has been found correlated with the synovial fluid level
of selected chemokines: CCR2 ligands (CCL2/MCP-1);
CCR5 ligands (CCL3/MIP-1α, CCL4/MIP-1β, and CCL5/
RANTES); CCR7 ligands (CCL19/MIP-3β and CCL21/
SLC), and CXCR4 ligand (CXCL12/SDF-1).
We will mainly focus on CCL2/MCP-1, as it is the major
chemokine active in macrophage recruitment and also
responsible for adipose tissue inflammation in obesity, where
the size of adipocytes correlates with MCP-1 levels [51].
Serum and synovial CCL2/MCP-1 levels are also strictly cor-
related with the pain score [142]. The understanding of the
molecular connections comes from studies carried out in
DMM models that demonstrate upregulation of both
CCL2/MCP-1 and CCR2 in the neurons of innervating dor-
sal root ganglia (DRG) in mice 8 weeks after DMM. The
CCL2/MCP-1 production by DRG neurons is once again
connected to molecular danger signals (S100A8 and α2 mac-
roglobulin) [143] originated in the joint after DMM and that
may diffuse to DRG and trigger TLR4 particularly on noci-
ceptive neurons. CCL2/MCP-1 release from DRG is respon-
sible for maximal macrophage infiltration at 8 weeks. CCR2
ablation indeed conferred protection with respect to pain
but not with respect to cartilage degradation [143]. The same
authors have recently shown that Ccl2 is the gene most
strongly upregulated immediately after the DMM. Ccl2−/−
or Ccr2−/− animals show an altered and delayed inflamma-
tory response but similar chondropathy scores compared to
their wild-type controls. Moreover, they show a significantly
delayed occurrence of pain [144]. Collectively, these data
suggest that the CCR2_ CCL2/MCP-1 axis may be targeted
for improving OA patients’ quality of life rather for control-
ling cartilage structural damage [144].
Other studies reported a different scenario, pointing at
a pivotal role of the CCR2_CCL2/MCP-1 axis also in
structural damage. Discrepancies of findings in DMM
studies may be related to the experimental design, includ-
ing susceptibility of the strain [7], details of gene knockout
(either full or tissue-specific and either constitutive or
inducible) or age at DMM surgery, and duration of OA
development in association with the timing of monitoring
(hours; 4, 8, 12, and 20 weeks). A recent study focused on
the transcriptional reprogramming that follows DMM at
early time, while vanishing at a later time. This study indi-
cated that at two weeks a significant upregulation was
found for the TGF signaling pathway and for complement
and coagulation cascade genes [145]. The upregulation of
TGF is of particular interest in the context of the activities
of the CCL2/CCR2 axis. Indeed, in a rat model of posttrau-
matic OA, Appleton and collaborators found that TGF2
and CCL2/MCP-1 were both upregulated at 4 weeks, with
the former inducing the expression of the latter and with
pharmacologic inhibition of either TGF2 or CCL2/MCP-
1 leading to attenuation of structural damage in both
in vivo or in vitro studies [146]. Notably, while the com-
plement cascade belongs to the family of the innate immu-
nity effectors and has been recently attributed a relevant
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Figure 3: Macro to micro views of changes occurring in articular cartilage during OA onset and development. Left images indicate healthy
joint, joint tissues, and chondrocytes. Resting chondrocytes present functional mitochondria and are surrounded by intact ECM. As a
consequence of different risk factors, profound changes occur in all the joint tissues. Right images indicate OA joint, crosstalk among OA
joint tissues, and hypertrophic chondrocytes. The latter present dysfunctional mitochondria, increased ROS production, and increased
IKKα expression and are surrounded by degraded ECM. ECM degradation products act as damage associated molecular patterns (DAMPs
or alarmins) recognized by the pattern recognition receptors (PRR) expressed by the cells. Alarmins are able to trigger both synovial
macrophages (via TLR2 and TLR4) and chondrocytes (via TLR2 and TLR4, and RAGE), thus sustaining synovial inflammation and
cartilage degradation. DAMPs also include HMGB1 that is highly expressed by both OA synoviocytes and hypertrophic chondrocytes and
is able to enhance NF-κB activation and release of chemokines (particularly of MCP-1, highly active in the recruitment of monocytes that
are also present in the synovial fluid) and cytokines, as well as of matrix metalloproteinases (MMPs) responsible for ECM remodeling and
loss of maturational arrest. Increased oxidative stress is both cause and consequence of mitochondrial dysfunction. Correction of major
risk factors and changes in diet and lifestyle can significantly reduce disease progression.
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role in mediating OA damage [147], the coagulation cas-
cade includes the activated protein C (APC), which may
act as an activator of cartilage matrix metalloproteinases
[148]. Another study carried out in the rat meniscal tear
OA model confirmed a strong upregulation of CCL2/
MCP-1 as early as day 3 [149].
The CCR2_CCL2/MCP-1 axis is critical for the recruit-
ment of macrophages to the joint [135]. CCR2-positive cells
(macrophages) are abundantly detected in human OA syno-
vial tissues and invade and erode cartilage in mouse OA
[135]. The CCR2_CCL2/MCP-1 axis is so strictly connected
with the pathogenesis of OA that a differential susceptibility
to this disease has been related to both disease-promoting
and disease-protective SNPs [150].
Synovial tissue specimens derived from OA patients
showed increased mRNA expression of many chemokines
active on monocytes and increased protein expression of
the corresponding chemokine receptors, but only CCL2/
MCP-1 and not CCL5/RANTES is significantly elevated in
synovial fluid of OA patients, suggesting that a hierarchical
selectivity exists for monocyte recruitment in OA, as also
confirmed in mouse OA pathogenesis [135].
Pharmacologic suppression of CCL2/MCP-1 expression
or CCR2 signaling significantly reduces OA progression
and relative cartilage structural damage via inhibition of
monocyte recruitment to synovial tissue and macrophage
accumulation. Interestingly, elevation of CCL2/MCP-1 in
synovial fluid has been pointed at as a reliable biomarker
for aseptic loosening of total knee arthroplasty and bone
loss [151].
Disruption of the CXCR4_CXCL12/SDF-1 axis led to
protection in a guinea pig model of spontaneous OA [152].
In this perspective, it is worthy to underline that circulating
HMGB1 may strengthen the downstream effects of this axis,
as previously reported [153].
An intriguing hypothesis is emerging that connects
innate immunity with the pathogenesis of many chronic
degenerative diseases including OA [154]. An unhealthy
microbiota composition together with an altered gut perme-
ability may allow for increased absorption and serum con-
centration of LPS. At the systemic level, LPS may activate
TLR on macrophages and trigger complement activation
yielding the production of bioactive components (C3a, C3b,
and C5a) that further enhance macrophage activation. LPS
is indeed found elevated in serum of OA patients and corre-
lated to knee joint narrowing [155]. To date, this mechanism
has been elegantly confirmed in rats in a study [156] that
teased out the pathogenesis of metOA associated with high-
fat diet and related alteration of microbiota composition.
Indeed, the animals treated with high-fat diet had higher
serum levels of LPS and fecal analysis pointed at the abun-
dance of particular species (Lactobacillus and Methanobrevi-
bacter) with strong predictive relationship with the modified
Mankin score.
5. Conclusion and Perspective
Latest literature findings have greatly added to the picture of
OA as a disease of accelerated aging of a postmitotic tissue
with little or no reparative potential, but within a framework
of systemic inflammation. Except for chronological issues, in
a biological sense, aging can be controlled and attenuated
with the adoption of dietary intervention and lifestyle mea-
sures that rescue the functionality of major homeostatic
mechanisms. In this perspective, it is worthy to underline
that state-of-the-art investigations revisited OA as belonging
to the so-called mismatch diseases, whose prevalence has
increased in the last decades because of higher exposure to
conditions that are far from those that were present when
our species has evolved. These conditions include circadian
rhythms, lifestyle, physical exercise, and diet. These factors
are amenable to correction, thus making OAmuch more pre-
ventable than currently considered [1].
In the lack of a true disease-modifying strategy, once OA
is established, a complete joint restitutio ad integrum appears
improbable, but much can be acted to slow OA progression
and delay the time of arthroplasty as well as controlling pain
and disability (as depicted in Figures 1 and 3).
Although targeting of selected cytokines or molecules
proved to be effective in delaying structural damage, more
promising are the strategies focused to counteract general
mechanisms of cell aging, such as via the use of dietary
restrictions or nutraceuticals able to reduce the magnitude
of insulin/IGF and mTOR signaling in favour of a stronger
sirtuin activation, thus exerting antiaging effects via rescue
of mitochondrial functionality, genome maintenance, and
proteostasis. A fundamental effect of this dietary strategy
is to promote clearance of damaged mitochondria, via
mitophagy [157, 158]. This at the same time allows reduc-
tion of oxidative damage and cell senescence [3, 46, 47]. As
an additional strategy, correction of intestinal microbiota
may be of help in maintaining the integrity of the intestinal
barrier and reducing adsorption of LPS, thus smoothing
innate immunity activation.
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